Chen Shouming, Wu Lan, Lang Bingchen, Zhao Guoyan, Zhang Wensheng
Department of Anesthesiology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China.
Front Pharmacol. 2025 May 14;16:1516991. doi: 10.3389/fphar.2025.1516991. eCollection 2025.
The sphingosine 1-phosphate (S1P) signaling pathway has important and diverse functions. S1P receptors (S1PRs) are involved in the regulation of lymphocyte trafficking, cardio-cerebral function, vascular permeability, and bronchiolar tone, and have been recognized as therapeutic targets for a variety of diseases. A number of drugs related to the S1P signaling pathway have been approved for clinical use in the treatment of multiple sclerosis, and many similar drugs are also currently being tested in clinical trials at various stages. It appears that S1PR modulators may not only be useful for the treatment of multiple sclerosis, but may also have therapeutic effects on other types of central nervous system (CNS) disorders. The present review focuses on the therapeutic potential of S1PR1 modulators for treating disorders of the CNS.
1-磷酸鞘氨醇（S1P）信号通路具有重要且多样的功能。S1P受体（S1PRs）参与淋巴细胞运输、心脑功能、血管通透性和细支气管张力的调节，并已被公认为多种疾病的治疗靶点。一些与S1P信号通路相关的药物已被批准用于治疗多发性硬化症的临床应用，目前许多类似药物也正在不同阶段的临床试验中进行测试。看来S1PR调节剂不仅可能对治疗多发性硬化症有用，而且可能对其他类型的中枢神经系统（CNS）疾病也有治疗作用。本综述重点关注S1PR1调节剂治疗中枢神经系统疾病的潜在治疗价值。
